Association of British Clinical Diabetologists (ABCD) position statement on the use of sodium-glucose cotransporter-2 inhibitors in type 1 diabetes (updated 2019)

Umesh Dashora, Dipesh C Patel, Robert Gregory, Peter Winocour, Ketan Dhatariya, Dinesh Nagi

Abstract


SGLT-2 inhibitors may be increasingly used in people with type 1 diabetes as new licenses are obtained. These drugs have the potential to improve glycaemic control in people with type 1 diabetes with the added benefit of weight loss, better control of blood pressure and more time in optimal glucose range. SGLT-2 inhibitors are associated with higher incidence of diabetic ketoacidosis without significant hyperglycaemia. The present ABCD position statement is to mitigate this risk and other potential complications in people taking these drugs. Particular caution needs to be exercised in people who are at risk of diabetic ketoacidosis due to low calorie diet, illnesses, injuries, starvation, excessive exercise, excessive alcohol consumption and reduced insulin administration among other precipitating factors for diabetic ketoacidosis.

Keywords


SGLT-2 inhibitors, type 1 diabetes, ketoacidosis, position statement

Full Text:

PDF HTML


DOI: https://doi.org/10.15277//bjd.2019.208

Refbacks

  • There are currently no refbacks.


The Journal of the Association of British Clinical Diabetologists